胆管がんの世界市場：治療タイプ別、流通チャネル別、地域別

世界の胆管がんの市場規模は、2025年には40億3,000万米ドルと推定され、2032年には71億8,000万米ドルに達すると予測され、2025年～2032年にCAGR8.6％で成長すると予測されています。

図.胆管がん市場シェア（%）、2025年、地域別

胆管がんは胆道がんとしても知られ、胆管にできるまれなタイプのがんです。胆管は肝臓と胆嚢を小腸につなぐ管です。胆管がんは、胆管に並ぶ細胞に異常が生じ、制御不能に増殖して腫瘍を形成することで発生します。 胆管がんを発症する主な危険因子としては、原発性硬化性胆管炎（PSC）、炎症性腸疾患、肝フルク、胆管の特定の先天異常などがあります。症状としては、黄疸、かゆみ、腹痛、体重減少、青白い便などがあります。診断には通常、超音波検査、CTスキャン、MRIスキャンなどの画像検査や生検が行われます。治療の選択肢はがんの病期によって異なり、手術、放射線療法、化学療法、標的療法などがあります。しかし、胆管がんは早期発見が難しく、腫瘍の増殖が遅いため、生存率が低く予後不良です。

市場力学：

世界の胆管がん市場の成長は、主にPSCや肝フルクスの感染などの危険因子の有病率の増加が牽引しています。米国疾病管理予防センター（CDC）によると、PSCは米国で約3万人が罹患しています。 胆管がんの理解不足や診断の遅れも、進行期での診断につながり、その結果、市場の成長を促進しています。さらに、胆管がんの治療成績を改善するための標的薬剤開発に向けた研究資金が増加していることも、市場関係者に有利な機会を提供する可能性があります。しかし、疾患認知度の低さや外科手術の複雑さが市場成長の妨げとなる可能性があります。

本調査の主な特徴

• 当レポートでは、世界の胆管がん市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模およびCAGR%を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案マトリクスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいて、世界の胆管がん市場における主要企業プロファイルを掲載しています。
• このレポートからの洞察は、マーケティング担当者や企業の経営陣が、将来の製品発売、タイプのアップグレード、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことを可能にします。
• 世界の胆管がん市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界の胆管がん市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 主な発展
• 規制シナリオ
• 買収と提携のシナリオ
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界の胆管がん市場：COVID-19パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 胆管がんの世界市場：治療タイプ別（2020年～2032年）

• 化学療法
• 標的療法
• 免疫療法
• その他

第6章 世界の胆管がん市場：流通チャネル別（2020年～2032年）

• 院内薬局
• 小売薬局
• オンライン薬局

第7章 世界の胆管がん市場：地域別（2020年～2032年）

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第8章 競合情勢

• 企業プロファイル
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Merck &Co., Inc.
  • Novartis AG
  • Celgene Corporation
  • Johnson &Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Fresenius Kabi AG
  • Mylan NV
  • ConMed Corporation
  • Boston Scientific Corporation
  • Taiho Pharmaceutical Co., Ltd.
  • Incyte Corporation

第9章 アナリストの推奨事項

• 運命の輪
• アナリストの見解
• Coherent Opportunity Map（COM）

第10章 参考文献と調査手法

• 参考文献
• 調査手法

Global Bile Duct Cancer Market is estimated to be valued at USD 4.03 Bn in 2025 and is expected to reach USD 7.18 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.

Figure. Bile Duct Cancer Market Share (%), By Region 2025

Bile duct cancer, also known as cholangiocarcinoma, is a rare type of cancer that forms in the bile duct. The bile duct is a tube that connects the liver and gallbladder to the small intestine. Bile duct cancer occurs when the cells that line the bile ducts become abnormal and grow uncontrollably, forming a tumor. Key risk factors for developing bile duct cancer include primary sclerosing cholangitis (PSC), an inflammatory bowel disease, liver flukes, and certain congenital abnormalities of the bile ducts. Symptoms may include jaundice, itching, abdominal pain, weight loss, and pale stools. Diagnosis usually involves imaging tests such as ultrasound, CT scan, and MRI scans, as well as biopsy. Treatment options depend on the stage of cancer and include surgery, radiation therapy, chemotherapy, and targeted therapy. However, bile duct cancer has a poor prognosis with low survival rates due to difficulties in early detection and slow growth nature of the tumors.

Market Dynamics:

Global bile duct cancer market growth is primarily driven by increasing prevalence of risk factors such as PSC and liver flukes infections. According to the Center for Disease Control and Prevention (CDC), PSC affects around 30,000 people in the U.S. Insufficient understanding and delays in diagnosing bile duct cancer also contribute to late-stage diagnosis, thus, driving the market growth. Moreover, rising research funding towards targeted drug development for improving the bile duct cancer treatment outcomes can offer lucrative opportunities for market players. However, low disease awareness and complexity in surgical procedures can hamper the market growth.

Key Features of the Study:

• This report provides in-depth analysis of the global bile duct cancer market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global bile duct cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eli Lilly, F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, and Bristol-Myers Squibb Company
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global bile duct cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bile duct cancer market

Detailed Segmentation-

• By Treatment Type
  • Chemotherapy
  • Gemcitabine
  • Cisplatin
  • Oxaliplatin
  • Capecitabine
  • 5 fluorouracil (5-FU)
  • Targeted Therapy
  • Pemigatinib
  • Infigratinib (Phase 3)
  • Ivosidenib (Phase 3)
  • Immunotherapy
  • (Pembrolizumab (Phase 3))

Others

• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Hoffmann-La Roche Ltd
  • Sanofi
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • Celgene Corporation
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Fresenius Kabi AG
  • Mylan N.V.
  • ConMed Corporation
  • Boston Scientific Corporation
  • Taiho Pharmaceutical Co., Ltd.
  • Incyte Corporation

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Bile Duct Cancer Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Bile Duct Cancer Market, By Treatment Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Chemotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Gemcitabine
  • Cisplatin
  • Oxaliplatin
  • Capecitabine
  • 5 fluorouracil (5-FU)
• Targeted Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Pemigatinib
  • Infigratinib (Phase 3)
  • Ivosidenib (Phase 3)
• Immunotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • (Pembrolizumab (Phase 3)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Bile Duct Cancer Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Bile Duct Cancer Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Company Profiles
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sanofi
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Celgene Corporation
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Johnson & Johnson Services, Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bayer AG
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Fresenius Kabi AG
  • Mylan N.V.
  • ConMed Corporation
  • Boston Scientific Corporation
  • Taiho Pharmaceutical Co., Ltd.
  • Incyte Corporation

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map
• References and Research Methodology
• References
• Research Methodology
• About us and Sales Contact